secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001728117-23-000009
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio pauses GB5121 enrollment, advances seralutinib Phase 3
-------------------------------------------------------------------

- Seralutinib Phase 3 in PAH to start H2 2023; dose 90 mg BID, primary endpoint 6-minute walk distance.
- TORREY open-label extension topline data expected mid-2023.
- GB5121 Phase 1b/2 enrollment paused due to benefit/risk profile and resource prioritization toward seralutinib.
- Cash of $255.7M at Dec 31, 2022; expected to fund operations into H2 2024.
- Full-year 2022 net loss $229.4M ($2.71/share), vs $234.0M ($3.13/share) in 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/0001728117-23-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/goss-20230317.htm
  HTML page:      https://secwatch.observer/filing/0001728117-23-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer